Mitochondrial dysfunction is not defined as an isolated “ATP problem” in the Hallmarks of Ageing framework, but as a systemic shift in bioenergetics, redox signaling, quality control and immune metabolism. In the Hallmark update (2023), the mitochondrial axis remains central and explicitly interacts with “disabled macroautophagy”, chronic inflammation and other Hallmarks. For medical practice, this entails a double task: to understand the mechanisms scientifically correctly (including their adaptivity and tissue specificity) and to keep the clinical translation evidence-based – especially where mitochondria-targeted interventions are increasingly marketed as “longevity”, but the data situation is still endpoint- and population-dependent.
Autoren
- Tanja Schliebe
Publikation
- Longevity-Special
You May Also Like
- From an antidiabetic drug to a distinct class of cardiorenal therapies
The Incretin Revolution in Cardiology
- Prostate Cancer
Intracrine and Metabolic Tumor Adaptation Under Androgen Deprivation
- Alopecia areata in children, adolescents, and adults
New Guideline Classifies the Evidence Base for Topical and Systemic Therapies
- Cardiology and Nutrition
Ultra-Processed Foods and Cardiovascular Risk—The New AHA Position
- Actinic keratoses
Targeted Treatment of Multiple AK Lesions—Balancing Efficacy and Convenience
- Obesity: A Multimodal and Interdisciplinary Approach
New Swiss Clinical Practice Guideline Provides Guidance
- cSCC: Personalizing Treatment Strategies and Follow-up Care Plans
Comprehensive risk stratification is no simple matter: what’s new?
- Baxdrostat – a new class of drugs for treating difficult-to-control hypertension